Bacterial DNA gyrase and topoisomerase IV — Drug Target

All drugs that target Bacterial DNA gyrase and topoisomerase IV — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Fluoroquinolone antibiotic · Fluoroquinolone antibiotic (as part of sequential therapy regimen) · Fluoroquinolone antibiotic (in combination therapy)

Marketed (10)

• Moxifloxacin (Topical) · University of California, San Francisco · Fluoroquinolone antibiotic · Infectious Disease / Ophthalmology
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.
• moxifloxacin 0.5% eye drops · Allergan · Fluoroquinolone antibiotic · Ophthalmology / Infectious Disease
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.
• Moxifloxacin HCl 0.5% · Carolina Eyecare Physicians, LLC · Fluoroquinolone antibiotic · Ophthalmology / Infectious Disease
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria.
• Vigamox Eye Drops · Merck Sharp & Dohme LLC · Fluoroquinolone antibiotic · Ophthalmology / Infectious Disease
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
• Cravit-based sequential therapy · National Taiwan University Hospital · Fluoroquinolone antibiotic (as part of sequential therapy regimen) · Infectious Disease / Gastroenterology
  Cravit-based sequential therapy uses levofloxacin (a fluoroquinolone antibiotic) as part of a multi-drug sequential regimen to eradicate Helicobacter pylori infection.
• levofloxacin-based triple therapy · National Taiwan University Hospital · Fluoroquinolone antibiotic (in combination therapy) · Infectious Disease / Gastroenterology
  Levofloxacin-based triple therapy combines a fluoroquinolone antibiotic with two other agents to eradicate Helicobacter pylori infection by inhibiting bacterial DNA gyrase and topoisomerase IV.
• Moxifloxacin 0.5% ophthalmic solution · Johns Hopkins University · Fluoroquinolone antibiotic · Ophthalmology / Infectious Disease
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death.
• Intracameral Moxifloxacin 0.1% · Suzan A Rattan · Fluoroquinolone antibiotic · Ophthalmology / Infectious Disease
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in bacteria.
• Third generation fluoroquinolone · University of Roma La Sapienza · Fluoroquinolone antibiotic · Infectious Disease
  Third-generation fluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.
• moxifloxacin 0.5% HCI ophthalmic solution · Allergan · Fluoroquinolone antibiotic · Ophthalmology / Infectious Disease
  Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death.

Phase 3 pipeline (5)

• OTO-201 (ciprofloxacin) · Otonomy, Inc. · Fluoroquinolone antibiotic · Otology / Infectious Disease
  OTO-201 is a sustained-release formulation of ciprofloxacin, a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV to kill bacteria in the middle ear.
• Gatifloxacin combined regimen · Institut de Recherche pour le Developpement · Fluoroquinolone antibiotic · Infectious Disease
  Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible microorganisms.
• Gemifloxacin-based triple therapy · Samsung Medical Center · Fluoroquinolone antibiotic · Infectious Disease
  Gemifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
• CXA-201 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Fluoroquinolone antibiotic · Infectious Disease
  CXA-201 is a novel antibiotic that inhibits bacterial protein synthesis by targeting the ribosome.
• Gatifloxacin 0.5% eye drops · Allergan · Fluoroquinolone antibiotic · Ophthalmology / Infectious Disease
  Gatifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription.